U.S. flag An official website of the United States government
  1. Home
  2. Advisory Committees
  3. Committees and Meeting Materials
  4. Blood, Vaccines and Other Biologics
  5. Vaccines and Related Biological Products Advisory Committee
  6. 2017 Meeting Materials, Vaccines and Related Biological Products Advisory Committee
  1. Blood, Vaccines and Other Biologics

2017 Meeting Materials, Vaccines and Related Biological Products Advisory Committee

2017 Meeting Materials, Vaccines and Related Biological Products Advisory Committee

November 7, 2017

On November 7, 2017, the Vaccines and Related Biological Products Committee (VRBPAC) will meet in an open session to discuss and make recommendations on the clinical development plan for Pfizer’s investigational Staphylococcus aureus vaccine intended for pre-surgical prophylaxis in elective orthopedic surgical populations.

October 4, 2017

On October 4, 2017, the Vaccines and Related Biological Products Committee (VRBPAC) will meet in an open session to discuss and make recommendations on the selection of strains to be included in an influenza virus vaccine for the 2018 southern influenza season.

September 13, 2017

On September 13, 2017, the Vaccines and Related Biological Products Committee (VRBPAC) will meet in an open session to discuss and make recommendations on the safety and effectiveness of Zoster Vaccine Recombinant (Adjuvanted) [Shingrix], manufactured by GlaxoSmithKline Biologicals.

July 28, 2017

On July 28, 2017, the Vaccines and Related Biological Products Committee (VRBPAC) will meet in an open session to discuss and make recommendations on the safety and efficacy of a Hepatitis B Vaccine manufactured by Dynavax.

May 17, 2017

On May 17, 2017, the Vaccines and Related Biological Products Committee (VRBPAC) will meet in an open session to discuss considerations for evaluation of Respiratory Syncytial Virus (RSV) vaccine candidates in seronegative infants.

March 9, 2017

On March 9, 2017, the committee will meet in open session to discuss and make recommendations on the selection of strains to be included in the influenza virus vaccines for the 2017-2018 influenza season.